These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22573655

  • 41. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH, Toussaint BW, Miller DM, Petersen MR, Foster RE, Riemann CD, Hutchins RK, Sisk RA.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [Abstract] [Full Text] [Related]

  • 42. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G, Marata AM, Magrini N, Bero L.
    Cochrane Database Syst Rev; 2014 Sep 15; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract] [Full Text] [Related]

  • 43. [Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].
    Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.
    Harefuah; 2008 Jul 15; 147(7):605-6, 662. PubMed ID: 18814519
    [Abstract] [Full Text] [Related]

  • 44. A poke in the eye.
    Gurney M.
    Nurs Older People; 2007 Dec 15; 19(10):3. PubMed ID: 18220056
    [No Abstract] [Full Text] [Related]

  • 45. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC.
    Clin Exp Ophthalmol; 2010 May 15; 38(4):333-4. PubMed ID: 20642588
    [No Abstract] [Full Text] [Related]

  • 46. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.
    Ophthalmologica; 2009 May 15; 223(6):370-5. PubMed ID: 19590252
    [Abstract] [Full Text] [Related]

  • 47. Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial.
    Foss AJ, Childs M, Reeves BC, Empeslidis T, Tesha P, Dhar-Munshi S, Mughal S, Culliford L, Rogers CA, Tan W, Montgomery A.
    Trials; 2015 Mar 10; 16():85. PubMed ID: 25873213
    [Abstract] [Full Text] [Related]

  • 48. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb 10; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 49. Costs of treatment for age-related macular degeneration.
    Gerson JD.
    Optometry; 2009 Jul 10; 80(7):339. PubMed ID: 19753688
    [No Abstract] [Full Text] [Related]

  • 50. I've heard that new medications to treat wet age-related macular degeneration (AMD) are available. Are these new medications better than current treatments?
    Johns Hopkins Med Lett Health After 50; 2006 Dec 10; 18(10):8. PubMed ID: 17290531
    [No Abstract] [Full Text] [Related]

  • 51. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV.
    Ophthalmology; 2013 May 10; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [Abstract] [Full Text] [Related]

  • 52. Treatment of exudative age-related macular degeneration: many factors to consider.
    Olsen TW.
    Am J Ophthalmol; 2007 Aug 10; 144(2):281-3. PubMed ID: 17659955
    [No Abstract] [Full Text] [Related]

  • 53. Ask the doctor. I have wet macular degeneration. I am trying to decide between Avastin and Lucentis. Which drug is better?
    Heier JS.
    Harv Health Lett; 2011 Dec 10; 37(2):6-7. PubMed ID: 27024308
    [No Abstract] [Full Text] [Related]

  • 54. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C, Harris J, Sulston J, Spanswick C.
    J Med Ethics; 2012 Mar 10; 38(3):187-9. PubMed ID: 21947806
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration.
    Azad R, Chandra P, Gupta R.
    Indian J Ophthalmol; 2007 Mar 10; 55(6):441-3. PubMed ID: 17951901
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.